(Dec 11th, 2024) The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precision for Better Translational Outcomes
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precision for Better Translational
Join us at WMIC 2023 Poster Session!
Discover groundbreaking research at Poster Session 3: Probes and Targets and Bioengineering, Basic Biology, and Synthetic Biology, scheduled for Friday, September 08, 2023, from 2:45 PM to 3:45 PM.
Immerse yourself in a world of innovation as we unveil the remarkable study titled:
🔬 Novel Fluorescent Regioselective Approach to Cyclize Phage-Displayed Peptides for SARS-CoV-2 Neutralization ðŸ¦
Abstract:
Using the regioselective cyanobenzothiazole condensation reaction with an N-terminal cysteine and the chloroacetamide reaction with an internal cysteine, a phage displayed macrocyclic 12-mer peptide library was constructed and subsequently validated. Using this library in combination with iterative selections against two epitopes from the receptor binding domain (RBD) of the novel severe acute respiratory syndrome virus 2 (SARS-CoV-2) Spike protein, macrocyclic peptides that strongly inhibit the interaction between the Spike RBD and angiotensin-converting enzyme 2 (ACE2), the human host receptor of SARS-CoV-2, were identified. The two epitopes were used instead of the Spike RBD to avoid selection of nonproductive macrocyclic peptides that bind RBD but do not directly inhibit its interactions with ACE2. Antiviral tests against SARS-CoV-2 showed that one macrocyclic peptide is highly potent against viral reproduction in Vero E6 cells with an EC50 value of 3.1 μM. The AlphaLISA-detected IC50 value for this macrocyclic peptide was 0.3 μM. The current study demonstrates that two kinetically controlled reactions toward N-terminal and internal cysteines, respectively, are highly effective in the construction of phage-displayed macrocyclic peptides, and the selection based on the SARS-CoV-2 Spike epitopes is a promising methodology in the identification of peptidyl antivirals.
Publication:
Publication Link: https://pubmed.ncbi.nlm.nih.gov/36174018/
Join us at WMIC 2023 as we illuminate the path to a safer and healthier world.
See you at the session!
🔗 Session Details:
Date: Friday, September 08, 2023
Time: 2:45 PM – 3:45 PM
Location: Prague Congress Centre
Don’t miss this opportunity to witness the future of viral neutralization.
WMIC Program: WMIC Program Link
The Paradigm Shift from Normoxia to Physoxia: Enhancing Experimental Precision for Better Translational
(November 14, 2024) NIR-II Fluorescence imaging: Why, When and How Short-Wave Infrared (SWIR)
(November 13, 2024) Reduce and Prevent Contamination in Tissue and Cell Culture Laboratories
(October 2, 2024) Next Generation Bioprinting Platform: A Multimodal Approach for Bioprinting of
(September 18, 2024) Gamma Eye calibration, system characterization, and in vivo imaging of
(July 24, 2024) Webinar: Lab Incubator Decontamination: Why, When and How Laboratory incubators